BDTX-1535 在胶质母细胞瘤或非小细胞肺癌患者中的研究
评估 BDTX-1535(一种口服 EGFR 抑制剂)在胶质母细胞瘤或非小细胞肺癌患者中的 1 期研究
BDTX-1535-101 is an open-label, Phase 1 dose escalation and Phase 2 multiple cohort study designed to evaluate the safety, pharmacokinetics (PK), optimal dosage, central nervous system (CNS) activity, and antitumor activity of silevertinib (BDTX-1535). The study population comprises adults with either advanced/metastatic non-small cell lung cancer (NSCLC) with non-classical or acquired epidermal growth factor receptor (EGFR) resistance (EGFR C797S) mutations with or without CNS disease (in Phase 1 and Phase 2), or glioblastoma (GBM) expressing EGFR alterations (Phase 1 only). All patients will self-administer silevertinib (BDTX-1535) monotherapy by mouth in 21-day cycles.
Phase 1 enrollment is now complete. Phase 2 is currently ongoing.
研究概览
地位
条件
研究类型
注册 (估计的)
阶段
- 阶段2
- 阶段1
联系人和位置
学习联系方式
- 姓名:BDTX Clinical Trial Navigation Service
- 电话号码:(866) 955-4397
- 邮箱:blackdiamondtx@careboxhealth.com
学习地点
-
-
British Columbia
-
Vancouver、British Columbia、加拿大、V5Z 4E6
- 招聘中
- BC Cancer Vancouver
-
接触:
- Vishaldeep Sidhu
- 电话号码:236-994-8251
- 邮箱:ClinicalTrialsHelp@bccancer.bc.ca
-
-
Ontario
-
Toronto、Ontario、加拿大、M5G 1X5
- 招聘中
- The Princess Margaret Cancer Centre
-
接触:
- Tuhina Paul
- 电话号码:416-946-4501 x 7890
- 邮箱:Tuhina.Paul@uhn.ca
-
-
-
-
Alabama
-
Birmingham、Alabama、美国、35294
- 招聘中
- University of Alabama
-
接触:
- Anna Wilbanks
- 电话号码:205-934-6454
- 邮箱:annaburton@uabmc.edu
-
-
Arizona
-
Gilbert、Arizona、美国、85234
- 招聘中
- Banner MD Anderson Cancer Center
-
接触:
- Brandi Luzania
- 电话号码:480-256-5488
- 邮箱:Brandi.Luzania@bannerhealth.com
-
-
California
-
Irvine、California、美国、92618
- 招聘中
- City of Hope Orange County Lennar Foundation Cancer Center
-
接触:
- 电话号码:626-218-1133
-
接触:
- Diana Patterson
- 电话号码:949-671-4763
-
Los Angeles、California、美国、90048
- 招聘中
- Cedars Sinai Medical Center
-
接触:
- Garret Crook
- 电话号码:424-314-0745
- 邮箱:Garrett.Crook@cshs.org
-
-
District of Columbia
-
Washington D.C.、District of Columbia、美国、20016
- 招聘中
- Sibley Memorial Hospital Johns Hopkins Medicine
-
接触:
- Judith Lawrence
- 电话号码:202-660-6500
- 邮箱:sibleyoncresreferral@live.johnshopkins.edu
-
-
Florida
-
Jacksonville、Florida、美国、32224
- 招聘中
- Mayo Clinic- Jacksonville
-
接触:
- Yanyan Lou
- 电话号码:855-776-0015
-
Miami、Florida、美国、33176
- 招聘中
- Miami Cancer Institute - Baptist Health South Florida
-
接触:
- Xiaoou Pan
- 电话号码:785-594-7856
- 邮箱:Xiaoou.pan@baptisthealth.net
-
-
Hawaii
-
Honolulu、Hawaii、美国、96813
- 招聘中
- UHP- University of Hawaii Cancer Center
-
接触:
- Evan Wu, MD
- 电话号码:808-586-3010
-
-
Illinois
-
Chicago、Illinois、美国、60611
- 招聘中
- Robert H. Lurie Comprehensive Cancer Center at Northwestern University
-
-
Massachusetts
-
Boston、Massachusetts、美国、02115
- 招聘中
- Dana-Farber Cancer Institute
-
接触:
- Dawn Bissessar
- 电话号码:617-632-5119
- 邮箱:dawn_bissessar@dfci.harvard.edu
-
-
Minnesota
-
Rochester、Minnesota、美国、55905
- 招聘中
- Mayo Clinic- Rochester
-
接触:
- Anastasios Dimou, MD
- 电话号码:855-776-0015
-
-
New York
-
The Bronx、New York、美国、10461
- 招聘中
- Montefiore Medical Center
-
接触:
- Balazs Halmos, MD
- 电话号码:718-405-8404
- 邮箱:bahalmos@montefiore.org
-
-
Pennsylvania
-
Pittsburgh、Pennsylvania、美国、15232
- 招聘中
- University of Pittsburgh Medical Center - Hillman Cancer Center
-
接触:
- Jennifer Ruth
- 邮箱:ruthj2@upmc.edu
-
-
Tennessee
-
Nashville、Tennessee、美国、37203
- 招聘中
- Tennessee Oncology
-
接触:
- Melissa Johnson, MD
- 电话号码:615-320-5090
- 邮箱:melissa.johnson@scri.com
-
-
Virginia
-
Fairfax、Virginia、美国、22031
- 招聘中
- Inova Schar Cancer Institute
-
接触:
- Stephanie Van Bebber
- 电话号码:571-472-0213
- 邮箱:Stephanie.VanBebber@inova.org
-
Fairfax、Virginia、美国、22031
- 招聘中
- Next Oncology
-
接触:
- Rebecca Fisher
- 邮箱:rfisher@nextoncology.com
-
-
Washington
-
Seattle、Washington、美国、98109
- 招聘中
- Fred Hutchinson Cancer Center/University of Washington
-
接触:
- Sam Woodman
- 电话号码:206-606-6346
- 邮箱:swoodman@fredhutch.org
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Phase 2 Eligibility:
Key Inclusion Criteria Required for locally advanced or metastatic NSCLC:
-
Measurable disease by RECIST 1.1 criteria.
-
Adequate bone marrow or organ function.
-
Life expectancy of ≥ 3 months.
-
Sufficient performance status.
-
Confirmed NSCLC, without small cell lung cancer transformation with or without brain metastases.
-
Disease progression following or intolerance of standard of care (excluding patients in the treatment-naïve non-classical driver cohort):
- Cohort 1 (Non-Classical driver cohort): Advanced/metastatic NSCLC with a non-classical driver EGFR mutation (eg, G719X) following up to 2 lines of therapy with only 1 prior EGFR TKI regimen (third-generation preferred; other approved EGFR TKI acceptable).
- Cohort 2 (Acquired resistance C797S cohort): Advanced/metastatic NSCLC with the acquired resistance C797S EGFR mutation following up to 2 lines of therapy, including only one EGFR TKI, which must be a third generation EGFR TKI (eg, osimertinib).
- Cohort 3 and 4 (First-line non-classical driver cohort): Treatment-naïve advanced/metastatic NSCLC with a non-classical driver EGFR mutations (1 cycle of chemotherapy or immune checkpoint inhibitor are permitted). Patients with co-occurring L858R mutations and a non-classical mutation are eligible for inclusion.
-
Identification of one (or more) of the following EGFR mutations by Next Generation Sequencing (NGS) as determined by a local assay performed in a validated laboratory in the absence of other known resistance mutations (eg, T790M, MET):
- Non-classical driver EGFR mutations (eg, L861R, S768I, G719X).
- EGFR acquired resistance mutation (eg, C797S) to a 3rd generation EGFR TKI.
- For Phase 2, dose expansion, patients in Cohort 1 who received 3rd generation EGFR TKI (eg, osimertinib), the NGS report within 6 months prior to the start of Screening is acceptable. For patients in Cohort 2, the NGS report must be from the last disease progression on the immediate prior therapy. For patients in Cohort 3 and 4, the NGS report must be at the time of diagnosis.
Key Exclusion Criteria:
- Known resistant mutations in tumor tissue or by liquid biopsy (eg, T790M, MET).
- Received more than 1 EGFR TKI therapy (ie, erlotinib or gefitinib) for the treatment of metastatic or recurrent EGFR NSCLC.
- Any history of interstitial lung disease related to EGFR TKI use.
- Symptomatic or radiographic leptomeningeal disease.
- Symptomatic brain metastases or spinal cord compression requiring urgent clinical intervention.
- Unresolved toxicity from prior therapy.
- Significant cardiovascular disease.
- Major surgery within 4 weeks of study entry or planned during study.
- Ongoing or recent anticancer therapy or radiation therapy.
- Evidence of malignancy (other than study-specific malignancies) requiring active therapy within the next 2 years.
- Active hepatitis B or C infection and/or known human immunodeficiency virus (HIV) carrier.
- Poorly controlled gastrointestinal disorders.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:非随机化
- 介入模型:顺序分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Phase 1 Dose Escalation - Monotherapy (Recruitment Closed)
|
Silevertinib (BDTX-1535) is a 4th generation irreversible brain penetrant EGFR MasterKey inhibitor, which targets a family of oncogenic EGFR classical and non-classical driver and resistance mutations in NSCLC.
其他名称:
|
|
实验性的:Phase 2 Cohort 1: NSCLC EGFR Non-Classical Driver Mutations (Recruitment Closed)
Advanced/metastatic NSCLC with a non-classical driver EGFR mutation following up to 2 lines of therapy with only 1 prior EGFR targeted regimen (third-generation preferred; other approved EGFR inhibitors acceptable) |
Silevertinib (BDTX-1535) is a 4th generation irreversible brain penetrant EGFR MasterKey inhibitor, which targets a family of oncogenic EGFR classical and non-classical driver and resistance mutations in NSCLC.
其他名称:
|
|
实验性的:Phase 2 Cohort 2: NSCLC EGFR Acquired Resistance (C797S) Mutation (Recruitment Closed)
Advanced/metastatic NSCLC with the acquired resistance C797S EGFR mutation following up to 2 lines of therapy, including only 1 EGFR targeted regimen, which must be a third generation EGFR TKI (eg, osimertinib) |
Silevertinib (BDTX-1535) is a 4th generation irreversible brain penetrant EGFR MasterKey inhibitor, which targets a family of oncogenic EGFR classical and non-classical driver and resistance mutations in NSCLC.
其他名称:
|
|
实验性的:Phase 2 Cohort 3: Treatment Naive NSCLC EGFR Non-Classical Driver Mutations (Recruitment Closed)
Treatment-naïve (first-line) advanced/metastatic NSCLC with a non-classical driver EGFR mutation (1 cycle of chemotherapy or immune checkpoint inhibitor are permitted). Patients with co-occurring L858R mutations and a non-classical mutation are eligible for inclusion. Silevertinib dose for Cohort 3 is 200 mg QD. |
Silevertinib (BDTX-1535) is a 4th generation irreversible brain penetrant EGFR MasterKey inhibitor, which targets a family of oncogenic EGFR classical and non-classical driver and resistance mutations in NSCLC.
其他名称:
|
|
实验性的:Phase 2 Cohort 4: Treatment Naive NSCLC EGFR Non-Classical Driver Mutations at 150 mg QD Dose
Treatment-naïve (first-line) advanced/metastatic NSCLC with a non-classical driver EGFR mutation (1 cycle of chemotherapy or immune checkpoint inhibitor are permitted). Patients with co-occurring L858R mutations and a non-classical mutation are eligible for inclusion. Silevertinib dose for Cohort 4 is 150 mg QD. |
Silevertinib (BDTX-1535) is a 4th generation irreversible brain penetrant EGFR MasterKey inhibitor, which targets a family of oncogenic EGFR classical and non-classical driver and resistance mutations in NSCLC.
其他名称:
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Phase 1 Dose Escalation: To determine the maximum tolerated dose (MTD), if one exists, and the preliminary recommended Phase 2 dose(s) (RP2D[s]) of silevertinib (BDTX-1535)
大体时间:The first treatment 21-day cycle (Cycle 1)
|
Dose-limiting toxicities (DLTs) in Cycle 1 |
The first treatment 21-day cycle (Cycle 1)
|
|
Phase 2 (Cohorts 1, 2, and 3): To assess antitumor efficacy of silevertinib (BDTX-1535)
大体时间:Day 1 every 2 cycles starting on Cycle 3 Day 1 to study completion, approximately 1 year (each cycle is 21 days)
|
Objective response rate (ORR) as assessed by Investigator using RECIST version 1.1 |
Day 1 every 2 cycles starting on Cycle 3 Day 1 to study completion, approximately 1 year (each cycle is 21 days)
|
|
Phase 2 Cohort 4 Only: To assess the safety and tolerability of silevertinib at the 150 mg QD dose
大体时间:Through study completion, approximately 1 year
|
Treatment-emergent adverse events |
Through study completion, approximately 1 year
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
第 2 阶段:通过 RECIST 1.1 版评估无进展生存期
大体时间:从第 3 周期开始,每 2 个周期第 1 天 第 1 天至研究完成,大约 1 年(每个周期 21 天)
|
从第 3 周期开始,每 2 个周期第 1 天 第 1 天至研究完成,大约 1 年(每个周期 21 天)
|
|
|
阶段1:通过RECIST 1.1(对于NSCLC患者)评估Silevertinib(BDTX-1535)的初步抗肿瘤活性(BDTX-1535)(对于NSCLC患者)或神经肿瘤学(RANO)(RANO)的反应评估(对于GBM患者)
大体时间:每2天从第3天开始学习完成的每2天,大约1年(每个周期为21天)
|
每2天从第3天开始学习完成的每2天,大约1年(每个周期为21天)
|
|
|
Phase 2 Cohort 4 Only: To assess antitumor efficacy of silevertinib (BDTX-1535)
大体时间:Day 1 every 2 cycles starting on Cycle 3 Day 1 to study completion, approximately 1 year (each cycle is 21 days)
|
Objective response rate (ORR) as assessed by Investigator using RECIST version 1.1 |
Day 1 every 2 cycles starting on Cycle 3 Day 1 to study completion, approximately 1 year (each cycle is 21 days)
|
合作者和调查者
调查人员
- 研究主任:Black Diamond Therapeutics、Black Diamond Therapeutics
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
关键字
- EGFR抑制剂
- 脑转移瘤
- EGFR L858R
- 中枢神经系统转移
- 颅内疾病
- 表皮生长因子受体改变
- 中枢神经系统转移
- EGFR 外显子 19 缺失
- 固有耐药 NSCLC EGFR
- 获得性耐药 NSCLC EGFR
- 罕见 NSCLC EGFR 突变
- C797S 获得性耐药 EGFR 突变
- 非经典 NSCLC EGFR 突变
- 经典 NSCLC EGFR 突变
- 第二位点 EGFR 突变
- EGFR PACC NSCLC 突变
- EGFR E709A/G/K/Q/V
- EGFR E709_T710delinsD/T
- EGFR G719A/C/D/R/S
- EGFR G724S
- EGFR L718Q/V
- EGFR L747S/P、L747_A750delinsP、L747_P753delinsS
其他相关的 MeSH 术语
其他研究编号
- BDTX-1535-101
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.